PDSB
PDS Biotechnology·NASDAQ
--
--(--)
--
--(--)
6.39 / 10
Outperform
Analyst sentiment is strongly bullish—both analysts rate Strong Buy, weighted rating 5.48—while fund‑flow scores 7.3/10, despite overall negative inflow ratios. However, the stock price dropped 14.4%, creating a divergence between optimism and market performance.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-13
InstitutionHC Wainwright & Co.
Times predicted4
Historical Win Rate25.0%
What is the analyst consensus for PDSB?
- PDSB holds a Bullish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.39/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
